Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia

NCT ID: NCT04637724

Last Updated: 2023-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-29

Study Completion Date

2023-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For the present study, Investigators will examine the efficacy of active prefrontal anodal tDCS versus placebo (sham) interventions to treat WM dysfunction in schizophrenia.

Investigators selected the prefrontal stimulation modality that proved most effective in enhancing high-load WM performance in single dose stimulation in healthy participants . The study employs a multi-stimulation approach, with 2 sessions per day for 5 consecutive days in the active treatment group (n=15) compared to a group that receives only sham stimulation (n=15). This preliminary approach is based upon findings of a recent study applying cathodal tDCS stimulation over left temporoparietal cortex (with left prefrontal anodal stimulation) for the treatment of persistent auditory hallucinations in schizophrenia. In a a recent study clinical benefits were maintained for at least 3 months following stimulation. In the present study, in addition to clinical outcome, researchers will evaluate whether similar improvement can be obtained with WM, EEG activity, and functional outcome (e.g., discharged from hospitalization following significant improvement or remission).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In a recent tDCS study investigators conducted with 41 healthy participants, researchers administered a single blind tDCS protocol that included an active unilateral DLPFC condition (2 mA for 15 minutes, anode over the left DLPFC (midpoint between F3-AF3) and cathode over the dorsal area of the superior parietal cortex (at Cz) versus a sham condition to investigate changes in online working memory function. Our preliminary tDCS results indicated gender-dependent (left enhancement in males versus females) high-load WM enhancement during active prefrontal stimulation versus sham stimulation. The observed prefrontal tDCS enhancing effect on high-load WM function indicated that left DLPFC tDCS could be implemented with SZP who suffer from inefficient left DLPFC engagement during medium to high-load WM maintenance.

Given the lack of effective treatments for attenuating WM impairments and the importance of these impairments to functional outcome in schizophrenia, tDCS based cognitive-enhancing approaches may become an important new treatment method, which will consequently improve treatment and functional outcome in schizophrenia patients.The innovative nature of the study's proposed research project is that it promotes non-invasive focal (left prefrontal cortex) neuromodulation to improve cognitive functioning as well as illness severity in SZP. Most importantly, unlike antipsychotic medication that affects the entire brain circuitry and produces undesired side effects (e.g., extrapyramidal effects, weight gain, hyperlipidemia, and sexual dysfunction), the current non-invasive focal intervention is aimed at reducing specific prefrontal dysfunctions in schizophrenia by specific targeting of prefrontal electrophysiological disturbances (e.g., frontal theta synchrony) within regions known to regulate behavior and the consolidation of goal-directed information.

Hypothesis Essentially, currently proposed tDCS treatment is hypothesized to improve working memory functioning and reduce symptom severity in people diagnosed with schizophrenia versus sham prefrontal tDCS (placebo).The theoretical premise for our prediction implies that effective inhibition of excessive dopaminergic mesolimbic activity (impaired in schizophrenia), could result from excitatory left-prefrontal tDCS, which has been shown to increase executive regulation of behavior in healthy individuals and people diagnosed with schizophrenia .

Research plan outline For the present study, investigators will examine the efficacy of active prefrontal anodal tDCS versus placebo (sham) interventions to treat WM dysfunction in schizophrenia. Investigatros selected the prefrontal stimulation modality that proved most effective in enhancing high-load WM performance in single dose stimulation in healthy participants. A multi-stimulation approach is implemnted, with 2 sessions per day for 5 consecutive days in the active treatment group (n=15) compared to a group that receives only sham stimulation (n=15). This preliminary approach is based upon findings of a recent study applying cathodal tDCS stimulation over left temporoparietal cortex (with left prefrontal anodal stimulation) for the treatment of persistent auditory hallucinations in schizophrenia . In a recent study clinical benefits were maintained for at least 3 months following stimulation. In the present study, in addition to clinical outcome, we will evaluate whether similar improvement can be obtained with WM, EEG activity, and functional outcome (e.g., discharged from hospitalization following significant improvement or remission).

In regards to efficacy, since WM is considered a core cognitive deficit in schizophrenia, investigators will monitor working memory, psychosis severity and global outcome, at baseline, immediately following tDCS intervention, and at 1, 4, and 8, 12, and 16 week intervals, following the termination the five-day treatment. Importantly, in order to show external validity of our efficacy analysis we will examine functional outcome (level of independence), six months after the termination of the tDCS intervention.

Finally, since DLPFC stimulation may contribute to long-term electroencephalography (EEG) theta- rhythm functional connectivity, associated with increased large-scale theta synchronization, WM function, and episodic memory formation, investigatros will examine effects of tDCS on prefrontal versus whole-brain EEG theta activity obtained during a WM task (see verbal n-Back task), using event-related potential (ERP) and event-related spectral power (ERSP) techniques similar to those in used in recent EEG studies in schizphrenia patients. Demonstrating significant functional-connectivity EEG differences in responders versus non-responders from baseline to post-intervention measurements will significantly increase the validity of our proposed prefrontal pathophysiological mechanism as significantly impacting psychosis severity and clinical outcome in schizophrenia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Schizo Affective Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Active tDCS versus Sham tDCS intervention
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

active tDCS

active prefrotal tDCS: 20 mins pes tDCS session, twice a day for 5 days. Total of 10 ative tDCS sessions.

Group Type EXPERIMENTAL

transcranial direct current stimulation (tDCS)

Intervention Type DEVICE

10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.

Sham tDCS

Sham prefrontal tDCS: sham stimulation 20 mins per session, twice a day for 5 days. Total of 10 sham stimulation sessions

Group Type SHAM_COMPARATOR

transcranial direct current stimulation (tDCS)

Intervention Type DEVICE

10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transcranial direct current stimulation (tDCS)

10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prefrontal tDCS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 18-75
* Primary diagnosis of DSM-IV schizophrenia (including schizoaffective disorder)
* Right handed
* Under stable doses of antipsychotic medication for ≥4 weeks
* Normal vision by self report and physical exam
* Use of effective method of birth control for women of childbearing capacity
* Willing/capacity to provide informed consent
* Outpatients or volunteering inpatients or involuntary patients with consent of legal guardian.

Exclusion Criteria

* Current or past history of substance dependence or abuse (excluding nicotine)
* Other current Axis I disorders
* History of seizure, epilepsy in self or first degree relatives, stoke, brain surgery, head injury, intracranial metal implants, known structural brain lesion, devices that may be affected by tDCS (pacemaker, medication pump, cochlear implant, implanted brain stimulator)
* Frequent and persistent migraines
* History of adverse reaction to neurostimulation
* Participation in study of investigational medication within 6 weeks
* Pregnancy
* Women who are breast-feeding
* Current significant laboratory abnormality
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oded Meiron

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Oded Meiron

Director of Non-invasive Brain Stimulation Clinic

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alex Borochov, MD

Role: PRINCIPAL_INVESTIGATOR

Herzog Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herzog Medical Center

Jerusalem, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

References

Explore related publications, articles, or registry entries linked to this study.

Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, Saoud M, Mechri A, Poulet E. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012 Jul;169(7):719-24. doi: 10.1176/appi.ajp.2012.11071091.

Reference Type BACKGROUND
PMID: 22581236 (View on PubMed)

Meiron O, Yaniv A, Rozenberg S, David J. Transcranial direct-current stimulation of the prefrontal cortex enhances working memory and suppresses pathological gamma power elevation in schizophrenia. Expert Rev Neurother. 2024 Feb;24(2):217-226. doi: 10.1080/14737175.2023.2294150. Epub 2024 Feb 6.

Reference Type DERIVED
PMID: 38084398 (View on PubMed)

Meiron O, David J, Yaniv A. Left prefrontal transcranial direct-current stimulation reduces symptom-severity and acutely enhances working memory in schizophrenia. Neurosci Lett. 2021 Jun 11;755:135912. doi: 10.1016/j.neulet.2021.135912. Epub 2021 Apr 21.

Reference Type DERIVED
PMID: 33894334 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

337-19

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of Negative Symptoms and Schizophrenia
NCT02204787 COMPLETED PHASE1/PHASE2
tDCS to Enhance Cognitive Training in Schizophrenia
NCT01733602 COMPLETED PHASE1/PHASE2